This ATM offering creates extreme and immediate dilution risk. Traders should expect continued downward pressure on the stock price as the company sells shares into the market. The company's pivot to an unproven AI platform and its explicit going concern warning suggest the stock could face further devaluation or potential delisting. Avoid long positions and consider the high probability of further capital raises.
Price Chart
Executive Summary
KALA BIO filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $250,000,000 in common stock through H.C. Wainwright. This massive potential dilution—up to 337.8 million shares at the current $0.78 price, more than 17x the existing 19.3 million shares outstanding—signals severe financial distress for a company with no revenue, no ongoing clinical trials, and a market cap of only $14M. The filing explicitly warns of going concern risk, Nasdaq delisting risk, and the need for additional capital, making this a deeply bearish event for existing shareholders.
Key Facts
- KALA BIO entered into an ATM Sales Agreement with H.C. Wainwright to sell up to $250,000,000 of common stock.
- At the July 17, 2026 closing price of $0.78, this represents up to 337,837,838 shares, which is over 17x the current 19,339,786 shares outstanding.
- The company has no ongoing clinical trials after the CHASE Phase 2b trial failed in September 2025, and is pivoting to an unproven AI platform-as-a-service business.
- The filing explicitly mentions risks related to going concern, Nasdaq delisting (stock recently traded below $1.00), and the need for additional financing.
- The company reported a net loss of $26,980 (in thousands) for FY2025 and $38,511 (in thousands) for FY2024, with no revenue.
- The shelf registration (S-3) was declared effective on June 25, 2026, and this is the first takedown under it.
Financial Impact
Up to $250,000,000 in potential gross proceeds from ATM sales, representing massive dilution of over 17x current shares outstanding at the current stock price.
Risk Factors
- Massive dilution of over 17x current shares outstanding from the ATM offering.
- Going concern risk and potential Nasdaq delisting if the stock price fails to maintain the $1.00 minimum bid.
- No revenue, no approved products, and a failed clinical pipeline with an unproven pivot to an AI platform business.
- History of frequent dilutive offerings (12 offering/registration filings in the last 24 months) and poor historical stock performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001829126-26-007754 |
| Document: 0001829126-26-007754-index-headers.html | 0001829126-26-007754 |
| Document: 0001829126-26-007754-index.html | 0001829126-26-007754 |
| Document: 0001829126-26-007754.txt | 0001829126-26-007754 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | 8-K | $0.6901 $0.4502 | ▲ +34.76% | ▲ +35.02% | $0.3884 (+43.72%) |
Jul 22, 2026 10w ago | 424B5 | $0.6103 $0.8401 | ▼ −37.65% | ▼ −34.35% | $0.3884 (+36.36%) |
Jun 26, 2026 14w ago | EFFECT | $2.52 $0.6103 | ▲ +75.78% | ▲ +77.04% | $0.3884 (+84.59%) |
May 7, 2026 21w ago | S-3 | $3.95 $2.06 | ▼ −47.85% | ▼ −47.87% | $0.3884 (−90.17%) |
Mar 4, 2026 30w ago | Press Release | $17.25 $0.1630 | ▼ −99.06% | ▼ −94.64% | $0.3884 (−97.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access